Importance of hepatitis C virus-associated insulin resistance: Therapeutic strategies for insulin sensitization

被引:46
作者
Kawaguchi, Takumi [1 ,2 ]
Sata, Michio [1 ,2 ]
机构
[1] Kurume Univ, Sch Med, Dept Digest Dis Informat & Res, Kurume, Fukuoka 8300011, Japan
[2] Kurume Univ, Sch Med, Dept Med, Kurume, Fukuoka 8300011, Japan
关键词
Hepatitis C virus; Diabetes mellitus; Insulin resistance; Complications; Treatments; Branched-chain amino acid; CHAIN AMINO-ACIDS; LATE EVENING SNACK; ZINC SUPPLEMENTATION IMPROVES; TYPE-2; DIABETES-MELLITUS; DIPEPTIDYL-PEPTIDASE-IV; HEPATOCELLULAR-CARCINOMA; LIVER-DISEASE; EXTRAHEPATIC MANIFESTATIONS; RECEPTOR SUBSTRATE-1; BLOOD-GLUCOSE;
D O I
10.3748/wjg.v16.i16.1943
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Insulin resistance is one of the pathological features in patients with hepatitis C virus (HCV) infection. Generally, persistence of insulin resistance leads to an increase in the risk of life-threatening complications such as cardiovascular diseases. However, these complications are not major causes of death in patients with HCV-associated insulin resistance. Indeed, insulin resistance plays a crucial role in the development of various complications and events associated with HCV infection. Mounting evidence indicates that HCV-associated insulin resistance may cause (1) hepatic steatosis; (2) resistance to anti-viral treatment; (3) hepatic fibrosis and esophageal varices; (4) hepatocarcinogenesis and proliferation of hepatocellular carcinoma; and (5) extrahepatic manifestations. Thus, HCV-associated insulin resistance is a therapeutic target at any stage of HCV infection. Although the risk of insulin resistance in HCV-infected patients has been documented, therapeutic guidelines for preventing the distinctive complications of HCV-associated insulin resistance have not yet been established. In addition, mechanisms for the development of HCV-associated insulin resistance differ from lifestyle-associated insulin resistance. In order to ameliorate HCV-associated insulin resistance and its complications, the efficacy of the following interventions is discussed: a late evening snack, coffee consumption, dietary iron restriction, phlebotomy, and zinc supplements. Little is known regarding the effect of anti-diabetic agents on HCV infection, however, a possible association between use of exogenous insulin or a sulfonylurea agent and the development of HCC has recently been reported. On the other hand, insulin-sensitizing agents are reported to improve sustained virologic response rates. In this review, we summarize distinctive complications of, and therapeutic strategies for, HCV-associated insulin resistance. Furthermore, we discuss supplementation with branched-chain amino acids as a unique insulin-sensitizing strategy for patients with HCV-associated insulin resistance. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:1943 / 1952
页数:10
相关论文
共 145 条
[1]  
Ajjan Ramzi A, 2006, Diab Vasc Dis Res, V3, P147, DOI 10.3132/dvdr.2006.023
[2]   Amino Acid Substitutions in the Hepatitis C Virus Core Region of Genotype 1b Are the Important Predictor of Severe Insulin Resistance in Patients Without Cirrhosis and Diabetes Mellitus [J].
Akuta, Norio ;
Suzuki, Fumitaka ;
Hirakawa, Miharu ;
Kawamura, Yusuke ;
Yatsuji, Hiromi ;
Sezaki, Hitomi ;
Suzuki, Yoshiyuki ;
Hosaka, Tetsuya ;
Kobayashi, Masahiro ;
Kobayashi, Mariko ;
Saitoh, Satoshi ;
Arase, Yasuji ;
Ikeda, Kenji ;
Kumada, Hiromitsu .
JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (06) :1032-1039
[3]   EVIDENCE FOR A LINK BETWEEN HEPATITIS-C VIRUS-INFECTION AND DIABETES-MELLITUS IN A CIRRHOTIC POPULATION [J].
ALLISON, MED ;
WREGHITT, T ;
PALMER, CR ;
ALEXANDER, GJM .
JOURNAL OF HEPATOLOGY, 1994, 21 (06) :1135-1139
[4]  
Amer Diabet Assoc, 2002, DIABETES CARE, V25, P202, DOI [10.2337/diacare.25.1.148, 10.2337/diacare.25.1.202]
[5]  
[Anonymous], J AM DENT ASS
[6]  
*ASPEN BOARD DIR C, 2002, JPEN J PARENTER ENTE, V26
[7]   Impaired IRS-1/PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes [J].
Aytug, S ;
Reich, D ;
Sapiro, LE ;
Bernstein, D ;
Begum, N .
HEPATOLOGY, 2003, 38 (06) :1384-1392
[8]   Drug therapy - Metformin [J].
Bailey, CJ ;
Turner, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) :574-579
[9]  
BIANCHI G, 1994, HEPATOLOGY, V20, P119, DOI 10.1016/0270-9139(94)90143-0
[10]   Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma [J].
Boissan, M ;
Beurel, E ;
Wendum, D ;
Rey, C ;
Lécluse, Y ;
Housset, C ;
Lacombe, ML ;
Desbois-Mouthon, C .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 167 (03) :869-877